Shares of Teva Pharmaceuticals are up 7.03% to $56.15 at the start of trading on Wednesday, according to an article in The Street, after increasing its second-quarter forecast and promoting its Allergan deal is on schedule and could close any day now.
Teva now anticipates second-quarter revenues between $4.9 billion and $5 billion vs. past estimates between $4.8 billion and $4.9 billion. Read the full story